Aptose Biosciences (NASDAQ:APTO) Given New $2.00 Price Target at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price objective decreased by HC Wainwright from $7.00 to $2.00 in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com assumed coverage on shares of Aptose Biosciences in a research report on Wednesday, November 13th. They issued a “hold” rating for the company.

Aptose Biosciences Stock Performance

Shares of APTO opened at $0.19 on Wednesday. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.61. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.91. The stock has a market capitalization of $3.44 million, a price-to-earnings ratio of -0.06 and a beta of 1.26.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.